Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mangoceuticals (MGRX) Total Liabilities (2023 - 2025)

Mangoceuticals' Total Liabilities history spans 3 years, with the latest figure at $804275.0 for Q3 2025.

  • For Q3 2025, Total Liabilities fell 42.7% year-over-year to $804275.0; the TTM value through Sep 2025 reached $804275.0, down 42.7%, while the annual FY2024 figure was $1.4 million, 416.4% up from the prior year.
  • Total Liabilities for Q3 2025 was $804275.0 at Mangoceuticals, down from $1.6 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $1.6 million in Q2 2025 and bottomed at $240684.0 in Q3 2023.
  • The 3-year median for Total Liabilities is $1.3 million (2024), against an average of $955675.5.
  • The largest annual shift saw Total Liabilities skyrocketed 483.15% in 2024 before it plummeted 42.7% in 2025.
  • A 3-year view of Total Liabilities shows it stood at $276039.0 in 2023, then surged by 416.4% to $1.4 million in 2024, then tumbled by 43.58% to $804275.0 in 2025.
  • Per Business Quant, the three most recent readings for MGRX's Total Liabilities are $804275.0 (Q3 2025), $1.6 million (Q2 2025), and $1.5 million (Q1 2025).